Faruqi & Faruqi Investigates Immutep Securities Litigation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 48 minutes ago
0mins
Should l Buy IMMP?
Source: Globenewswire
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential securities fraud claims against Immutep (NASDAQ: IMMP), particularly for investors who purchased securities between March 24, 2025, and March 12, 2026, urging them to seek lead plaintiff status by the July 6, 2026 deadline, indicating significant legal risks for the company.
- Clinical Trial Failure: Immutep faced a major setback in its TACTI-004 Phase III clinical trial, with the Independent Data Monitoring Committee recommending trial discontinuation due to failure to meet primary efficacy and safety endpoints, resulting in an 82.6% drop in stock price on March 13, 2026, causing substantial financial losses for investors.
- False Statement Allegations: The lawsuit alleges that Immutep and its executives violated federal securities laws by making false or misleading statements regarding the TACTI-004 trial, concealing material adverse facts that could mislead investors about the company's prospects.
- Investor Rights Protection: Faruq & Faruqi encourages anyone with information regarding Immutep's conduct, including whistleblowers and former employees, to come forward to provide legal support for affected investors, ensuring their rights are protected.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMMP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMMP
Wall Street analysts forecast IMMP stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.460
Low
12.00
Averages
12.00
High
12.00
Current: 0.460
Low
12.00
Averages
12.00
High
12.00
About IMMP
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Faruqi & Faruqi Investigates Immutep Securities Litigation
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential securities fraud claims against Immutep (NASDAQ: IMMP), particularly for investors who purchased securities between March 24, 2025, and March 12, 2026, urging them to seek lead plaintiff status by the July 6, 2026 deadline, indicating significant legal risks for the company.
- Clinical Trial Failure: Immutep faced a major setback in its TACTI-004 Phase III clinical trial, with the Independent Data Monitoring Committee recommending trial discontinuation due to failure to meet primary efficacy and safety endpoints, resulting in an 82.6% drop in stock price on March 13, 2026, causing substantial financial losses for investors.
- False Statement Allegations: The lawsuit alleges that Immutep and its executives violated federal securities laws by making false or misleading statements regarding the TACTI-004 trial, concealing material adverse facts that could mislead investors about the company's prospects.
- Investor Rights Protection: Faruq & Faruqi encourages anyone with information regarding Immutep's conduct, including whistleblowers and former employees, to come forward to provide legal support for affected investors, ensuring their rights are protected.
See More
Immutep Faces Class Action Lawsuit, Stock Price Plummets
- Class Action Filed: A securities class action lawsuit has been initiated in the Southern District of New York against Immutep, covering all investors who purchased American Depositary Receipts between March 24, 2025, and March 12, 2026, highlighting significant investor concern over the company's transparency.
- Allegations of Misrepresentation: The complaint alleges that defendants provided positive statements while concealing critical adverse facts regarding the efficacy and safety of the TACTI-004 Phase III clinical trial, potentially misleading investors into making uninformed decisions.
- Trial Discontinuation Impact: On March 13, 2026, Immutep announced that the Independent Data Monitoring Committee recommended discontinuing the TACTI-004 trial due to a planned interim futility analysis, leading to a collapse in investor confidence.
- Stock Price Collapse: Following the announcement, Immutep's ADR price plummeted from $2.76 per share on March 12, 2026, to $0.48 per share on March 13, 2026, marking an approximately 83% decline, reflecting extreme pessimism regarding the company's future prospects.
See More
Immutep Faces Class Action Lawsuit, Stock Plummets 83%
- Class Action Initiated: Immutep Limited is facing a class action lawsuit for disseminating false information between March 24, 2025, and March 12, 2026, under case number 1:26-cv-03705, indicating significant risks in its clinical trials that could lead to investor losses.
- Stock Price Crash: Following the announcement on March 13, 2026, that the TACTI-004 Phase III clinical trial was discontinued due to futility, Immutep's ADR price plummeted from $2.76 to $0.48, representing an approximately 83% decline, severely impacting investor confidence.
- Investor Compensation Commitment: Levi & Korsinsky LLP is committed to securing full compensation for investors who suffered losses due to corporate misrepresentations, urging IMMP shareholders to step forward by the July 6, 2026 deadline to seek justice.
- Law Firm's Track Record: Over the past 20 years, Levi & Korsinsky has secured hundreds of millions for aggrieved shareholders and has extensive expertise in complex securities litigation, being ranked among the top securities litigation firms in the U.S. for seven consecutive years, showcasing its capability in handling such cases.
See More
Immutep Faces Securities Claims Investigation
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Immutep Ltd. (NASDAQ: IMMP) for possibly issuing materially misleading business information, highlighting significant deficiencies in the company's information transparency.
- Stock Price Plunge Impact: On March 13, 2026, Immutep's ADR price fell by $2.28, or 82.6%, after the Independent Data Monitoring Committee recommended discontinuing the TACTI-004 Phase III study, reflecting extreme market pessimism regarding the company's future prospects.
- Class Action Preparation: Rosen Law Firm is preparing a class action against Immutep, allowing investors to seek compensation without any out-of-pocket fees, indicating that the legal risks faced by the company may further exacerbate its financial pressures.
- Law Firm Background: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling similar cases.
See More
Rosen Law Firm Investigates Immutep Securities Claims
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Immutep Ltd. (NASDAQ: IMMP) due to allegations of issuing materially misleading business information, indicating significant legal risks for the company.
- Stock Price Plunge: On March 13, 2026, Immutep's ADR price fell by $2.28, or 82.6%, to close at $0.48 after the Independent Data Monitoring Committee recommended discontinuing the TACTI-004 Phase III study, reflecting extreme market pessimism about the company's future.
- Class Action Preparation: The Rosen Law Firm is preparing a class action against Immutep, allowing investors to seek compensation without any out-of-pocket fees, suggesting the company may face substantial legal liabilities.
- Firm's Strength: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its strong capabilities and successful track record in the securities litigation field.
See More
Rosen Law Firm Investigates Securities Claims for Immutep Shareholders
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Immutep Ltd. (NASDAQ:IMMP) for possibly issuing materially misleading business information, indicating significant legal risks for the company.
- Stock Price Plunge: On March 13, 2026, Immutep's ADR price fell by $2.28, or 82.6%, to close at $0.48 after the Independent Data Monitoring Committee recommended discontinuation of the TACTI-004 Phase III study, reflecting market pessimism about the company's future.
- Class Action Preparation: The Rosen Law Firm is preparing a class action for affected investors, allowing them to seek compensation without any out-of-pocket costs, demonstrating the firm's commitment to protecting investor rights.
- Firm's Strength: Known for its successful track record in securities class actions, Rosen Law Firm recovered over $438 million for investors in 2019 alone, highlighting its leadership and expertise in the industry.
See More
Faruqi & Faruqi Investigates Immutep Securities Litigation
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential securities fraud claims against Immutep (NASDAQ: IMMP), particularly for investors who purchased securities between March 24, 2025, and March 12, 2026, urging them to seek lead plaintiff status by the July 6, 2026 deadline, indicating significant legal risks for the company.
- Clinical Trial Failure: Immutep faced a major setback in its TACTI-004 Phase III clinical trial, with the Independent Data Monitoring Committee recommending trial discontinuation due to failure to meet primary efficacy and safety endpoints, resulting in an 82.6% drop in stock price on March 13, 2026, causing substantial financial losses for investors.
- False Statement Allegations: The lawsuit alleges that Immutep and its executives violated federal securities laws by making false or misleading statements regarding the TACTI-004 trial, concealing material adverse facts that could mislead investors about the company's prospects.
- Investor Rights Protection: Faruq & Faruqi encourages anyone with information regarding Immutep's conduct, including whistleblowers and former employees, to come forward to provide legal support for affected investors, ensuring their rights are protected.
See More
Immutep Faces Class Action Lawsuit, Stock Price Plummets
- Class Action Filed: A securities class action lawsuit has been initiated in the Southern District of New York against Immutep, covering all investors who purchased American Depositary Receipts between March 24, 2025, and March 12, 2026, highlighting significant investor concern over the company's transparency.
- Allegations of Misrepresentation: The complaint alleges that defendants provided positive statements while concealing critical adverse facts regarding the efficacy and safety of the TACTI-004 Phase III clinical trial, potentially misleading investors into making uninformed decisions.
- Trial Discontinuation Impact: On March 13, 2026, Immutep announced that the Independent Data Monitoring Committee recommended discontinuing the TACTI-004 trial due to a planned interim futility analysis, leading to a collapse in investor confidence.
- Stock Price Collapse: Following the announcement, Immutep's ADR price plummeted from $2.76 per share on March 12, 2026, to $0.48 per share on March 13, 2026, marking an approximately 83% decline, reflecting extreme pessimism regarding the company's future prospects.
See More
Immutep Faces Class Action Lawsuit, Stock Plummets 83%
- Class Action Initiated: Immutep Limited is facing a class action lawsuit for disseminating false information between March 24, 2025, and March 12, 2026, under case number 1:26-cv-03705, indicating significant risks in its clinical trials that could lead to investor losses.
- Stock Price Crash: Following the announcement on March 13, 2026, that the TACTI-004 Phase III clinical trial was discontinued due to futility, Immutep's ADR price plummeted from $2.76 to $0.48, representing an approximately 83% decline, severely impacting investor confidence.
- Investor Compensation Commitment: Levi & Korsinsky LLP is committed to securing full compensation for investors who suffered losses due to corporate misrepresentations, urging IMMP shareholders to step forward by the July 6, 2026 deadline to seek justice.
- Law Firm's Track Record: Over the past 20 years, Levi & Korsinsky has secured hundreds of millions for aggrieved shareholders and has extensive expertise in complex securities litigation, being ranked among the top securities litigation firms in the U.S. for seven consecutive years, showcasing its capability in handling such cases.
See More
Immutep Faces Securities Claims Investigation
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Immutep Ltd. (NASDAQ: IMMP) for possibly issuing materially misleading business information, highlighting significant deficiencies in the company's information transparency.
- Stock Price Plunge Impact: On March 13, 2026, Immutep's ADR price fell by $2.28, or 82.6%, after the Independent Data Monitoring Committee recommended discontinuing the TACTI-004 Phase III study, reflecting extreme market pessimism regarding the company's future prospects.
- Class Action Preparation: Rosen Law Firm is preparing a class action against Immutep, allowing investors to seek compensation without any out-of-pocket fees, indicating that the legal risks faced by the company may further exacerbate its financial pressures.
- Law Firm Background: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling similar cases.
See More
Rosen Law Firm Investigates Immutep Securities Claims
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Immutep Ltd. (NASDAQ: IMMP) due to allegations of issuing materially misleading business information, indicating significant legal risks for the company.
- Stock Price Plunge: On March 13, 2026, Immutep's ADR price fell by $2.28, or 82.6%, to close at $0.48 after the Independent Data Monitoring Committee recommended discontinuing the TACTI-004 Phase III study, reflecting extreme market pessimism about the company's future.
- Class Action Preparation: The Rosen Law Firm is preparing a class action against Immutep, allowing investors to seek compensation without any out-of-pocket fees, suggesting the company may face substantial legal liabilities.
- Firm's Strength: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its strong capabilities and successful track record in the securities litigation field.
See More
Rosen Law Firm Investigates Securities Claims for Immutep Shareholders
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Immutep Ltd. (NASDAQ:IMMP) for possibly issuing materially misleading business information, indicating significant legal risks for the company.
- Stock Price Plunge: On March 13, 2026, Immutep's ADR price fell by $2.28, or 82.6%, to close at $0.48 after the Independent Data Monitoring Committee recommended discontinuation of the TACTI-004 Phase III study, reflecting market pessimism about the company's future.
- Class Action Preparation: The Rosen Law Firm is preparing a class action for affected investors, allowing them to seek compensation without any out-of-pocket costs, demonstrating the firm's commitment to protecting investor rights.
- Firm's Strength: Known for its successful track record in securities class actions, Rosen Law Firm recovered over $438 million for investors in 2019 alone, highlighting its leadership and expertise in the industry.
See More
